Bicara Therapeutics (NASDAQ:BCAX) Reaches New 1-Year High After Analyst Upgrade

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) reached a new 52-week high during trading on Wednesday after The Goldman Sachs Group raised their price target on the stock from $14.00 to $16.00. The Goldman Sachs Group currently has a neutral rating on the stock. Bicara Therapeutics traded as high as $21.05 and last traded at $20.5040, with a volume of 90918 shares. The stock had previously closed at $19.89.

Other equities analysts also recently issued reports about the stock. Bank of America started coverage on shares of Bicara Therapeutics in a report on Wednesday, March 25th. They set a “buy” rating and a $35.00 target price for the company. BTIG Research reissued a “buy” rating on shares of Bicara Therapeutics in a research note on Thursday, January 15th. Wells Fargo & Company lifted their price objective on Bicara Therapeutics from $11.00 to $16.00 and gave the stock an “equal weight” rating in a research report on Tuesday. Wedbush reaffirmed an “outperform” rating and issued a $30.00 target price on shares of Bicara Therapeutics in a research note on Tuesday. Finally, UBS Group reiterated a “buy” rating on shares of Bicara Therapeutics in a report on Wednesday, January 14th. Eight equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Bicara Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $28.00.

Insider Transactions at Bicara Therapeutics

In other Bicara Therapeutics news, CFO Ivan Hyep sold 13,555 shares of the stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $18.22, for a total value of $246,972.10. Following the completion of the sale, the chief financial officer owned 145,355 shares of the company’s stock, valued at $2,648,368.10. This trade represents a 8.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Claire Mazumdar sold 36,766 shares of Bicara Therapeutics stock in a transaction on Monday, March 9th. The stock was sold at an average price of $19.17, for a total transaction of $704,804.22. Following the sale, the chief executive officer directly owned 339,392 shares in the company, valued at $6,506,144.64. This trade represents a 9.77% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 137,969 shares of company stock valued at $2,586,198. 15.50% of the stock is currently owned by company insiders.

Key Headlines Impacting Bicara Therapeutics

Here are the key news stories impacting Bicara Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its 2026 quarterly and full‑year EPS forecasts (Q1–Q4 and FY2026) and reiterated a “Buy” rating with a $42 price target — the firm trimmed expected losses for each quarter and the year, signaling improved analyst confidence. Read More.
• Positive Sentiment: Wedbush reaffirmed an “Outperform” rating on BCAX, adding third‑party validation from another biopharma‑focused shop that can boost investor sentiment. Read More.
• Positive Sentiment: Goldman Sachs published bullish commentary indicating expected upside for BCAX, which helps drive demand from institutional and retail investors watching analyst cues. Read More.
• Positive Sentiment: Wells Fargo highlighted strong price‑appreciation potential for Bicara, contributing additional buy‑side momentum. Read More.
• Positive Sentiment: Aggregate Wall Street price targets (per Zacks) imply roughly ~55% upside from current levels — the headline can attract momentum traders and investors seeking high‑growth biotechs. Read More.
• Neutral Sentiment: Recent Q4 2025 results showed a slight beat to loss estimates (EPS better than consensus by $0.04), but the company remains unprofitable with consensus FY2026 EPS still a negative figure — investors are reacting to rate of improvement, not profitability yet. Read More.

Institutional Investors Weigh In On Bicara Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Legal & General Group Plc raised its stake in Bicara Therapeutics by 64.1% during the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after acquiring an additional 1,233 shares in the last quarter. Ameritas Investment Partners Inc. grew its stake in shares of Bicara Therapeutics by 73.0% in the second quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company’s stock worth $32,000 after purchasing an additional 1,474 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of Bicara Therapeutics by 419.3% during the second quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock valued at $44,000 after purchasing an additional 3,866 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Bicara Therapeutics during the fourth quarter valued at $45,000. Finally, Larson Financial Group LLC raised its stake in shares of Bicara Therapeutics by 1,015.5% during the third quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock valued at $62,000 after purchasing an additional 3,595 shares in the last quarter.

Bicara Therapeutics Stock Up 4.7%

The firm has a market capitalization of $1.41 billion, a P/E ratio of -8.49 and a beta of -1.23. The business’s 50 day moving average is $17.36 and its two-hundred day moving average is $16.73.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings results on Monday, March 30th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.04. As a group, equities analysts anticipate that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current fiscal year.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.